New Hypertriglyceridaemia Drug Receives Positive Opinion
The drug could reduce triglyceride levels and pancreatitis risk for adults with severe hypertriglyceridaemia.
Updated on Oct. 27, 2026 in Diabetes
Live Poll
Should regulatory bodies prioritize approving new RNA-targeted therapies for rare chronic conditions?
The European Medicines Agency has recommended the approval of olezarsen, a treatment for adults with severe hypertriglyceridaemia. The decision offers a potential new therapy for approximately 700,000 people across the EU5 who live with significantly elevated triglyceride levels.
Why it matters
Severe hypertriglyceridaemia poses a substantial risk for acute pancreatitis, a painful and potentially serious inflammation of the pancreas. This development provides a targeted clinical option to lower lipid levels and reduce the incidence of such events for high-risk patients.
A pooled analysis of clinical trials involving 1,063 adults with triglyceride levels of at least 500 mg/dL showed an 85% reduction in acute pancreatitis rates and up to a 72% drop in fasting triglycerides compared to placebo.
The players
European Medicines Agency
An agency of the European Union responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
Sobi
A biopharmaceutical company focused on developing therapies for people living with rare diseases.
The details
Olezarsen is administered as a subcutaneous injection at 50 mg or 80 mg doses every four weeks. It is intended to be used in combination with dietary modifications and existing lipid-lowering therapies to manage patients with fasting triglyceride levels of at least 880 mg/dL. By reducing triglyceride levels, the therapy aims to mitigate the risk of acute pancreatitis associated with severe hypertriglyceridaemia.
Timeline
The European Medicines Agency issued a positive opinion for the drug on October 27, 2026.
A final decision from the European Commission is expected in the fourth quarter of 2026.
Health Landscape
This recommendation fits into the ongoing evolution of lipid-lowering therapies beyond traditional statins. It addresses a specific, high-risk population for whom managing triglyceride-induced pancreatitis remains a critical unmet need in global health.
If you are managing severe hypertriglyceridaemia, this development is worth discussing with your physician to understand how new therapies might fit into your long-term management plan. Focus on maintaining your current prescribed lipid-lowering regimen and dietary goals while awaiting further regulatory updates.
The takeaway
Olezarsen may offer a significant pathway to reducing pancreatitis risk for those with extremely high triglyceride levels. Always track your fasting triglyceride levels through regular blood work and discuss any changes in your risk profile or potential new therapies with your primary care doctor.
What happens next
A final regulatory decision regarding the drug's authorization is anticipated from the European Commission in the fourth quarter of 2026.
Further reading
Learn more about managing metabolic health and related risks on our Diabetes page.
Source note: This article includes information reported by Pharmafile.
Live Poll
Should regulatory bodies prioritize approving new RNA-targeted therapies for rare chronic conditions?
